What is Aston Science?
Aston Science operates as a clinical-stage biopharmaceutical enterprise dedicated to the research and development of a sophisticated pipeline of innovative medicines. The company distinguishes itself through a specialized focus on therapeutic cancer vaccines, a high-growth sector within the broader immunotherapy market. By targeting complex oncological pathways, Aston Science aims to redefine standard-of-care protocols, positioning itself as a critical player in the global effort to improve patient outcomes through precision medicine and advanced biological therapeutics.
How much funding has Aston Science raised?
Aston Science has raised a total of $22.7M across 1 funding round:
Series C
$22.7M
Series C (2022): $22.7M with participation from Timefolio Asset Management and Mirae Asset Venture Investment
Key Investors in Aston Science
Timefolio Asset Management
A prominent investment firm focused on diversified asset management and strategic capital allocation across high-growth sectors.
Mirae Asset Venture Investment
A leading venture capital entity specializing in identifying and scaling innovative technology and life sciences companies globally.
What's next for Aston Science?
With the successful closure of this major strategic investment, Aston Science is poised to transition into a more aggressive phase of clinical validation and operational scaling. The capital will likely be deployed to expedite ongoing trials, expand the internal research and development infrastructure, and potentially facilitate strategic partnerships that enhance the commercial viability of its therapeutic pipeline. As the company moves deeper into its clinical roadmap, the focus will remain on achieving key regulatory milestones and demonstrating the efficacy of its vaccine candidates in diverse patient populations, thereby maximizing long-term shareholder value and clinical impact.
See full Aston Science company page
